chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I started to have muscle aches. I got tested two days later. I had a sore throat, coughing a runny nose and fatigue. My blood oxygen was very low, it was in the low 80s. I felt so bad and I isolated for 10 days. The cough was dry and constant and the only thing that helped was cough syrup. I was prescribed an inhaler, and antibiotics. I still have the cough after six weeks and I still have trouble catching my breath. My worst symptoms lasted for 7 days and I still felt very tired when I returned to work.
soreness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (soreness at the injection site) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced ARTHRALGIA (soreness at the injection site). At the time of the report, ARTHRALGIA (soreness at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case concerns an 88-year-old female who experienced a nonserious expected event of arthralgia. The event occurred the same day as the first dose of mRNA-1273. Treatment included Tylenol. Event outcome unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: This case concerns an 88-year-old female who experienced a nonserious expected event of arthralgia. The event occurred the same day as the first dose of mRNA-1273. Treatment included Tylenol. Event outcome unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Patient came to pharmacy complaining that she had a reaction to the the 2nd dose of SHINGRIX. She stated that the first dose was fine, the 2nd one caused her flu like symptoms and upset stomach for about 12 hours. She felt fine after approximately 12 hours.
Patient had unbelievable pain, which we explained could happen for a week or so. The patient still has the pain and it has been almost a month now. I called the doctor who prescribed the vaccine for the patient and they were going to call her and discuss it. Her arm was not red or have heat coming from it, so I ruled out infection I believe.
Screaming, crying, hitting stomach, problems sleeping, would wake up in pain-screaming, constipation, very sudden crying-like stabbing pains that would come and go, straining to poop but unable. This continues for about 6 weeks and slowly got better. Before the vaccination he used to poop 2-3 times a day. Patient required suppositories in order to poop for about 3 months proceeding the vaccination. Patient was exclusively breastfed and after receiving the vaccination his gas and poop smelled horrible-it never returned to normal.
the mother of the patient requested meningitis and the technician mistakenly entered mmr.  the error wasnt noticed till the mom gave the school the shot record and they said it was not the vaccine she needed.  the mom called when she found out it was wrong, 2 days later.  she said her daughter didnt experice any ill effects from getting the mmr but she still needed the meningitis vaccine.  they came back that afternoon, on 7/13/2023, and recieved the correct vaccine.  I contacted the local poison control to see if there were any known adverse events from getting this vaccine again for this patient.  They said the only effects they should expect were the usual possible pain at injection site and redness.  I passed this information on to mom at the time of giving the menveo.
WAS GIVEN PNUEMO VAC. ON FRIDAY AND SATURDAY HER ARM WAS ACHY AND SHE HAD SOME CHILLS AND ON SUNDAY HER ARM WAS SORE AND SHE RAN A LOW GRADE FEVER APPROX 99 AND HAD A WHITE ROUND CIRCLE AROUND INJECTION SITE AND HER ARM WAS STIFF WITH MOVEMENT.MONDAY SHE WOKE UP AND SHE HAS REDNESS UNDER THE INJECTION SITE AND SOME SWELLING THE APPROX SIZE OF A BASEBALL
pt recvd vax 4JAN93 & exp a recurrence of the sx; It resolved w/in 8 wks; No further details were provided;
Client denied in written format and verbally that he received any other vaccinations 14 days prior to receiving the COVID vaccination.  Client had received Hep B (HEPLISAV-B) on 3/18/2021
Alopecia totalis; Stress; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A 51 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ALOPECIA TOTALIS (non-serious), outcome "unknown", described as "My Pfizer Covid vaccination induced a case of Alopecia Totalis"; STRESS (non-serious), outcome "unknown", described as "This situation has already created 10 months of stress".  The lot number for bnt162b2 was not provided and will be requested during follow up.
Patient contracted COVID after being fully vaccinated Abdominal pain, nausea, anorexia, diarrhea, vomiting, headache
This spontaneous report as received from a 76 years old female patient with heart murmur, depression and arthritis refers to herself. The patient's medical history included 3 feet of her colon removed and gallbladder removed. The patient had no drug allergies. The patient was vaccinated with ZOSTAVAX (Lot#unspecified) in November-2009. Concomitant medications included: "Cholesterol medication Heart medication, anti-depression, NEURONTIN" and PREVACID. On 12-JUL-2012 the patient had a zoster breakout on her left eye. The patient was treated with NEURONTIN. The outcome was unknown. The patient had sought unspecified medical attention. Additional information has been requested.
This spontaneous report as received from nurse practitioner refers to a patient of unknown age and gender. No medical history and concurrent conditions reported. On 23-JUN-2015, the patient was inadvertently administered with improperly stored MMR II vaccine, lot # K002816, expire date: 25-FEB-2016 (dose, route, therapy type not reported). No adverse effects reported. No product quality complaint reported. This is one of several reports received from the same source. Additional information has been requested.
pt c/o pain lt arm, neck, chest stated started immediately p/inject & is persisting;
bedridden with an extreme reaction; she could not raise her arms; was unable to dress herself or do anything; lot of pain; aches in all joints, joint throbbed; fatigue, tired; Initial information received on 15-Jan-2020 regarding an unsolicited valid non-serious case received from a nurse.  This case involves a 65 years old female patient who experienced lot of pain (pain), bedridden with an extreme reaction (bedridden), aches in all joints, joint throbbed (arthralgia), she could not raise her arms (Movement disorder), was unable to dress herself or do anything (Loss of personal independence in daily activities) and fatigue (fatigue), while she received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  The patient's past vaccination(s) included INFLUENZA VACCINE.  The patient's past medical history, medical treatment(s) and family history were not provided.  On 11-Oct-2019, the patient received a 0.5 ml dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot number and expiry date: not reported) via unknown route in unknown administration site.  On 13-Oct-2019, the patient developed a non-serious aches in all joints, joint throbbed (arthralgia) and  fatigue, tired (fatigue ) two days following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE.  On an unknown date, the patient developed a non-serious lot of pain (pain) and was bedridden with an extreme reaction (bedridden) within 10 days, following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE. It was reported that, She was okay now, but for 10 days after the shot she had a pretty extreme reaction. On 21-Oct-2019, she went to see her doctor. During this time, she could not raise her arms (Movement disorder). Patient every joint throbbed. She was unable to dress herself or do anything (Loss of personal independence in daily activities). She was still under a doctor care.  Detail of laboratory data were not reported.  Final diagnosis was fatigue, bedridden, pain, Loss of personal independence in daily activities, Movement disorder and arthralgia.  It was not reported if the patient received a corrective treatment.  On an unknown date the patient was recovering from the events.  Information on the batch number was requested.
09:00 fever 101.1, facial flushing, generalized aching, history of covid-19, site erythema at 48h, nausea and fever resolved<24h
Patient received Moderna vaccine at age 17. Moderna is only approved for ages 18 and older. Patient unclear about her age at time of vaccine with no ID.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 21-APR-2016 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (lot # L040178, expiration date 18-AUG-2017). This specified lot number vaccine was exposed to temperature excursion two times. The total cumulative excursion time of the first time was 136 hours with the lowest recorded temperature of 33 Fahrenheit degree. The total cumulative excursion time of the second time was 40 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
6 days after second covid vaccine developed bronchospasm, body aches, difficulty breathing, short of breath, diarrhea, pleuritic chest pain
Case number PHEH2014US025838, is an initial spontaneous report received from a consumer (patient) on 23 Dec 2014. This report refers to a male patient of unknown age. His medical history and concomitant medication were not reported. He was vaccinated with FLUVIRIN (batch number: not reported) in upper arm on an unknown date. After receiving the vaccine, he experienced sustained vertigo. Medical measures were taken by him. Final outcome, seriousness and causality of the event were not reported.
Pt was given her 4th Anthrax vaccine one month early and was incorrectly administered distal to the deltoid. Also pt recieved the FLU vaccine on the same day. As a result on the following day, the patient c/o of flu like symptoms with fever, bodyaches, fatigue, abnormal swelling and redness in L arm from Anthrax vaccination.
Post Moderna 2nd vaccination on Sept 19th - 6 1/2 hrs post injection, became very ill for 2 days vomiting, fever and fatigue.  Then from Sept19th to Oct 6th experienced hot flashes/fatigue/HA/nausea/bloating/*intermittent acute visceral pain near spleen and appendix/*weird whole body tenderness to light touch trunk and extremities/persistent tickling cough; dwindling sxs through to Oct 13th.  An additional concerning response 1 week after the 2nd dose was inflammation of my intestines and vaginal region which was sore and when I moved my bowels or urinated, it felt as if my organs were going to fall out of my body.  This bizarre sxs lasted 9 days.  I have never had this complaint prior to Covid vaccine and has not returned since. Remaining sxs now are hormonal changes of my menstrual cycle which is occurring every 2-3 wks and lasting 2wks once arrived, along with continued HAs.  This same hormonal response began 1 week into having Covid in April 2020 and lasted 14 months post Covid, it normalized and began all over again 1 wk post 2nd vaccine.
small dot at the injection; tenderness at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site tenderness in a 57-year-old female patient who received Herpes zoster (Shingrix) (batch number H3MJ9, expiry date September 2021) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of extensive swelling of vaccinated limb (1st dose received on 14th March 2019. Please refer the case US2019104323).   On 10th July 2019, the patient received the 2nd dose of Shingrix. On 10th July 2019, less than a day after receiving Shingrix, the patient experienced injection site tenderness. On 11th July 2019, the patient experienced injection site macule. The patient was treated with benadryl (nos) (Benadryl). Rechallenge with Shingrix was positive. On an unknown date, the outcome of the injection site tenderness and injection site macule were unknown.   It was unknown if the reporter considered the injection site tenderness and injection site macule to be related to Shingrix.  Additional details were provided as follows: The patient received 2nd dose of Shingrix and experienced tenderness at the injection site. The patient reported that she took Benadryl 25 mg thirty minutes before the injection and another 25 mg that night before bedtime. When she woke up the next morning she had no tenderness and only saw a small dot at the injection site. The patient continued taking Benadryl 25 mg twice a day on the next two following days because she wanted to prevent any side effects she had experienced with the first Shingrix injection.
she has been diagnosed with bell's palsy. she was told that it would be temporoary.
Patients mother describes patient not moving as usual, not holding up bottle at feeding, not crawling as usual. Not moving as usual smiling or moving arms or legs. Not responding as usual.
Patient had a red, welt on her arm where she received vaccine.  The spot was warm to the touch and itchy.
patient described redness, soreness, and warmth on the area 6 days after vaccine, has taken tylenol for pain and cold compress
On Aug 8, 2022, I tested positive for Covid-19 with an antigen test at my hotel. I was staying at a hotel while attending my son's wedding a few days earlier. Approximately 1/2 of the 100 wedding guests became infected with Covid-19. The day after I tested positive, I started taking Paxlovid. Within 36 hours of starting the drug, I was essentially well, although my home antigen test still tested positive for Covid-19. The test did not show a negative result until Aug. 14th and Aug.15th.  On Aug. 19th I tested positive again for Covid-19 (Covid Rebound). For the next 3-days, I was fairly ill with flu like symptoms. On  Aug. 21st I experienced a new  and scary symptom of an accelerated heart rate that lasted for 6 hours. My normal resting heart rate is between 48 and 52 ( I exercise every day). On Sunday evening Aug. 21 my heart rate went from 50's up to 160 to 170 for 6 hours. My heart rate then gradually returned to normal during the next 24 hours. This accelerated heart rate symptom has not recurred. I did not take Paxlovid for my 2nd, Covid rebound case.  Since the beginning of September, I have returned to my full aerobic and weight machine exercise program. My aerobic workout is 45 minutes every other day on an Elliptical exercise machine. On the alternate days, I lift weights on 8 different machines for approximately 1 hour total at the local fitness center. My accelerated heart rate symptom has not returned.
Tingling sensation all over skin/light fine rash/<10 raised red areas, pinpoint. Denied itching, SOB, swelling in throat or tongue, increase heart rate, light headed or dizziness. Was given Benadryl 25mg P.O. by occupational nurse where pt works and observed for one hour. Symptoms subsided and was then taken to PCP where pt was evaluated and instructed could receive 2nd vaccine in 28 days but to take Benadryl 25mg P.O. one hour prior to vaccination time. Pt will will be observed for one hour after vaccination instead of standard 15 minutes. If symptoms return after observation time PCP instructed to take an additional 25mg Benadryl by mouth. EMS services are on site and available during the time of vaccination clinic.
Generalized seizures without ever having a seizure before; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number and expiry date not available), via an unspecified route of administration, Left arm on 08Apr2021 at 09:00 AM (at the age of 50-years-old) at a single dose for COVID-19 immunization. The patient's medical history was reported as none. The patient had no known allergies. Concomitant medication included celecoxib (CELEXA). The patient was vaccinated at a hospital. No other vaccine was given in four weeks. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient experienced generalized seizures without ever having a seizure before on 10Apr2021 at 15:00. The event caused hospitalization in Apr2021 and was also reported as life-threatening. The patient underwent lab tests and procedures which included nasal swab test: negative on 10Apr2021. Therapeutic measures taken as a result of the event included hospitalization and med flight, as reported. The outcome of the event was not recovered.  Information about lot/batch number has been requested.
Patient reported fatigue, sore arm, nausea and that he vomited bile once within 24 hours of vaccination
FATIGUE; NAUSEA; MYALGIA; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the patient experienced fatigue, nausea, and myalgia. The action taken with covid-19 vaccine was not applicable. The outcome of the fatigue, nausea and myalgia was not reported. This report was non-serious.
Pt recvd Engerix-B & devel fibromyalgia p/1st dose;
pt recvd vax 230PM; about 9PM same evening began to sneeze uncontrollably, legs went numb, ears tingling, face & eyes swelled to being shut; had severe abdo pain, couldn't talk, profuse sweating; became unconcious & stopped breathing;
Little soreness on his arm; Little bit tired; Bruising where he got the shot; Redness below the shot; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Little soreness on his arm), VACCINATION SITE BRUISING (Bruising where he got the shot), VACCINATION SITE ERYTHEMA (Redness below the shot) and FATIGUE (Little bit tired) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     No relevant Medical history Reported.  Concomitant products included WARFARIN for an unknown indication.    On 04-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Feb-2021, the patient experienced VACCINATION SITE BRUISING (Bruising where he got the shot) and VACCINATION SITE ERYTHEMA (Redness below the shot). On an unknown date, the patient experienced PAIN IN EXTREMITY (Little soreness on his arm) and FATIGUE (Little bit tired). At the time of the report, PAIN IN EXTREMITY (Little soreness on his arm), VACCINATION SITE BRUISING (Bruising where he got the shot), VACCINATION SITE ERYTHEMA (Redness below the shot) and FATIGUE (Little bit tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medications provided by the reporter   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Contain no new information.
More than 42 days after First shot and she has not received the Second dose/More then 50 days after 1st shot; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 42 days after First shot and she has not received the Second dose/More then 50 days after 1st shot) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 42 days after First shot and she has not received the Second dose/More then 50 days after 1st shot). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (More than 42 days after First shot and she has not received the Second dose/More then 50 days after 1st shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. Treatment medications were not provided by the reporter. The patient reported it have been more than 50 days after first dose.   Most recent FOLLOW-UP information incorporated above includes: On 16-Jun-2021: Follow-up information received on 16-JUN-2021: Event details added.
Erythema Multiforme - Nurse Practitioner gave patient Benadryl and recommended continuing q 6 hrs as needed. Symptoms subsided 8/13/12 by 9:00 AM.
patient presented requesting a 2nd dose of moderna vaccine after administrating vaccine we figured the patient is under the influence and after checking impact we found that patient had 5 doses of moderna and when we asked the patient and he said no he had only gotten one before at our location.
nausea; diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea) and NAUSEA (nausea) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID], ATORVASTATIN, HYDROCHLOROTHIAZIDE, AMLODIPINE and OMEPRAZOLE for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced DIARRHOEA (diarrhea). On 09-Mar-2021, the patient experienced NAUSEA (nausea). The patient was treated with BISMUTH SUBSALICYLATE (PEPTO BISMOL [BISMUTH SUBSALICYLATE]) at an unspecified dose and frequency. On 09-Mar-2021, DIARRHOEA (diarrhea) had resolved. At the time of the report, NAUSEA (nausea) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was linked to MOD-2021-039192 (Patient Link).